Other OTC - Delayed Quote • USD
Helix BioMedix, Inc. (HXBM)
At close: February 7 at 9:31 AM EST
Key Executives
Amounts are as of December 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Robin L. Carmichael | President, CEO & Director | 304.35k | -- | 1957 |
| Kelly Forsythe | Associate Director of Marketing | -- | -- | -- |
Helix BioMedix, Inc.
22121-17th Avenue SE
Suite 112
Bothell, WA 98021
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.
Corporate Governance
Helix BioMedix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available